From the Journals
Study Maps Delta-Like Protein 3 and SEZ6 Across Tumor Types
-
By
September 3, 2025
-
3 min
-
1
DLL3 and SEZ6 expressions are prominent in neuroendocrine neoplasms.
-
2
High-grade tumors like lung NECs show significant DLL3 positivity.
-
3
SEZ6 is most frequently expressed in medullary thyroid carcinomas.
-
4
The study analyzed 213 specimens, including NENs and non-NENs.
-
5
A semi-quantitative H-score was used to evaluate staining intensity.
-
Recent research focusing on Delta-like protein 3 (DLL3) and seizure-related 6 homolog (SEZ6) expression reveals significant associations in neuroendocrine neoplasms (NENs), especially high-grade tumors, such as lung neuroendocrine carcinomas and Merkel cell carcinomas. A study involving 213 tumor specimens categorized by the 2022 WHO guidelines assessed DLL3 and SEZ6 expression through immunohistochemical techniques. The findings indicate that DLL3 positivity is predominantly observed in high-grade NENs, while SEZ6 has broader expression across various types, including medullary thyroid carcinomas and duodenal NETs.
-
1
DLL3 and SEZ6 expressions are prominent in neuroendocrine neoplasms.
-
2
High-grade tumors like lung NECs show significant DLL3 positivity.
-
3
SEZ6 is most frequently expressed in medullary thyroid carcinomas.
-
4
The study analyzed 213 specimens, including NENs and non-NENs.
-
5
A semi-quantitative H-score was used to evaluate staining intensity.
Listen Tab content
